Technology | April 14, 2010

Small Gamma Camera Targets Prostate Cancer

ProxiScan

April 14, 2010 - For the first time, the U.S. Food and Drug Administration (FDA) gave 510(k) clearance to a gamma camera indicated for endocavity imaging.

The technology is designed to address a widespread need for higher quality nuclear-medical images for prostate cancer diagnosis. ProxiScan is a small cadmium zinc telluride (CZT)-based compact gamma camera developed by Hybridyne in collaboration with scientists at Brookhaven National Laboratory.

The system can be used in imaging the distribution of radionuclides in the human body, using planar imaging techniques. The system may also be used intraoperatively, on pathological specimens and for endocavity applications if a protective sheath is used. ProxiScan is also capable of imaging radiopharmaceuticals distributed within anatomical regions of interest located close to the camera head.

For more information: www.hybridyneimagingtechnologies.com

Related Content

advanced visualization
News | Molecular Imaging | June 09, 2017
The Food and Drug Administration (FDA) has cleared syngo.via VB20 for Molecular Imaging (MI) from Siemens Healthineers...
News | SPECT-CT | June 08, 2017
Siemens Healthineers debuts Symbia Intevo Bold at the 2017 annual meeting of the Society of Nuclear Medicine &...
Sponsored Content | Videos | Nuclear Imaging | April 28, 2017
David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the American S
SPECT/CT Imaging Test Shown Accurate in Ruling Out Kidney Cancers
News | SPECT Imaging | April 24, 2017
The latest in a series of studies led by researchers at Johns Hopkins Medicine shows that addition of a widely...
brain SPECT imaging, dementia, depression, Daniel G. Amen

Representative brain SPECT scans in a patient with Alzheimer's dementia showing substantially reduced brain blood flow in the temporal and parietal lobes compared to a person with depression with mild decreased frontal lobe blood flow. Image courtesy of Amen Clinics.

News | SPECT Imaging | February 22, 2017
February 22, 2017 — Does a patient have depression or a cognitive disorder (CD) such as Alzheimer's disease or both?
News | Nuclear Imaging | December 12, 2016
Molecular Targeting Technologies, Inc. (MTTI) announces that response of colorectal cancer to treatment can be detected...
xSPECT Quant technology, SPECT/CT, Symbia Intevo, Siemens Healthineers, RSNA 2016
News | SPECT Imaging | December 06, 2016
December 6, 2016 — At the 102nd Scientific Assembly and Annual Meeting of the Radiological Society of North America (
News | Radiopharmaceuticals and Tracers | September 06, 2016
Navidea Biopharmaceuticals Inc. announced that it has executed a Letter of Intent (LOI) with Cardinal Health for the...
UltraSPECT, Xpress3.Cardiac, nuclear imaging, RWJPE, New Jersey, Robert Wood Johnson Physician Enterprise
News | SPECT Imaging | July 25, 2016
UltraSPECT Inc. announced recently that Robert Wood Johnson Physician Enterprise (RWJPE), a multi-specialty, community-...
neuroendocrine tumors, NET, radiotherapy dose, PET, SPECT, SNMMI 2016

Comparison of Ga-68-DOTATOC PET/CT with Y-90 DOTATOC PET/CT. Although the positron associated with Y-90 is rarely emitted, there is still sufficient signal to acquire a quantitative PET/CT image of Y-90 DOTATOC after a therapeutic administration. The white arrows indicate kidneys and the yellow arrows tumor. Credit: University of Iowa

News | Nuclear Imaging | June 23, 2016
Aggressive neuroendocrine cancer is something of a dark horse — a rare, elusive and persevering force linked to...
Overlay Init